Assess whether RWE can replace or only supplement an RCT (3ae840)

Situation

An AdCom briefing document that overstates subgroup findings put scientific-advice briefing book in front of RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / Pharmacovigilance close is RWE can replace or from scientific-advice briefing book, and the live options are RWE can replace, Only supplement an RCT.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize RWE can replace now; scientific-advice briefing book already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep Only supplement an RCT in force until scientific-advice briefing book is completed after an AdCom briefing document that overstates subgroup findings for RWE evidence-strategy director.
• Treat scientific-advice briefing book as RWE can replace because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page RWE can replace or turns on in scientific-advice briefing book.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• For this Pharma & Life Sciences Pharmacovigilance file, read scientific-advice briefing book against an AdCom briefing document that overstates subgroup findings and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.